<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00573560</url>
  </required_header>
  <id_info>
    <org_study_id>US PARACHUTE Protocol</org_study_id>
    <nct_id>NCT00573560</nct_id>
  </id_info>
  <brief_title>Safety Study of the Ventricular Partitioning Device (VPD) Implant System in Heart Failure Patients</brief_title>
  <acronym>PARACHUTE</acronym>
  <official_title>A Feasibility Trial to Evaluate the VPD Implant System - Percutaneous Ventricular Restoration in Chronic Heart Failure Due to Ischemic Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardioKinetix, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CardioKinetix, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CardioKinetix Ventricular Partitioning Device (VPD) is intended to isolate the&#xD;
      malfunctioning portion of the left ventricle in patients with symptoms of heart failure due&#xD;
      to ischemic heart disease. By isolating the malfunctioning portion of the left ventricle, it&#xD;
      is hypothesized that the left ventricle will pump more effectively.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of safety defined as the successful delivery and deployment of the VPD Implant through 6 month follow up without the occurrence of Major Adverse Cardiac Events (MACE) related to the investigational device.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary Effectiveness Measurements at 6 months - Change in LV volume indices (LVESVI, LVEDVI, EF) - Change in 6 minute walk and VO2 max - Cardiovascular mortality and morbidity inclusive of hospitalization for HF, MI and stroke</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VPD Implant System</intervention_name>
    <description>Percutaneous introduction using standard catheterization techniques of the VPD Implant.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Akinesis or dyskinesis due to myocardial infarction limited to anteroapical region&#xD;
&#xD;
          2. Diagnosis of heart failure for a minimum of 6 months prior to enrollment&#xD;
&#xD;
          3. NYHA Class at time of enrollment, either:&#xD;
&#xD;
               -  NYHA Class III or IV - if predominant during the 3-month period prior to&#xD;
                  enrollment&#xD;
&#xD;
               -  NYHA Class II - if diagnosed with NYHA Class III or IV during 3-month period&#xD;
                  prior to enrollment and ≥ 1 hospitalization for heart failure during 12-month&#xD;
                  period prior to enrollment&#xD;
&#xD;
          4. LVEF ≤ 40% as measured by echocardiography&#xD;
&#xD;
          5. Left ventricle must have appropriate anatomy as measured by Cardiac CT per the VPD&#xD;
             Implant sizing criteria described in the device's Instructions For Use&#xD;
&#xD;
          6. Eligible for cardiac surgery&#xD;
&#xD;
          7. Between 18 and 74 years of age (inclusive)&#xD;
&#xD;
          8. Receiving appropriate medical treatment for heart failure according to the ACC/AHA&#xD;
             2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the&#xD;
             Adult during the three months prior to enrollment&#xD;
&#xD;
          9. Female patients with childbearing potential must have a negative pregnancy test&#xD;
             (within 7 days of the procedure) and must agree not to attempt to become pregnant&#xD;
             during the course of the study&#xD;
&#xD;
         10. Provide written informed consent&#xD;
&#xD;
         11. Agree to the protocol-required follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Myocardial ischemia requiring PCI or CABG&#xD;
&#xD;
          2. Acute MI (see MI definition) within 60 days of enrollment or patients with suspected&#xD;
             evolving MI at time of enrollment&#xD;
&#xD;
          3. Cardiogenic shock within 72 hours of enrollment&#xD;
&#xD;
          4. Revascularization procedure (PCI or CABG) within 60 days of enrollment&#xD;
&#xD;
          5. Patient has received a CRT device within 60 days of enrollment&#xD;
&#xD;
          6. Patient diagnosed with significant valve disease (AI &gt;1+; MR &gt;2+) which may or may not&#xD;
             require surgery&#xD;
&#xD;
          7. Patient has received an ICD within 60 days of enrollment&#xD;
&#xD;
          8. Patient has received a pacemaker within 60 days of enrollment&#xD;
&#xD;
          9. History of aborted sudden cardiac death, if patient has not received an ICD and has&#xD;
             potentially lethal ventricular arrhythmia, VT or VF&#xD;
&#xD;
         10. Patients with a history or a current diagnosis of either persistent or paroxysmal&#xD;
             atrial fibrillation as well as patients who present with a contraindication to oral&#xD;
             anticoagulant therapy&#xD;
&#xD;
         11. Aortic valve replacement or repair&#xD;
&#xD;
         12. Resting systolic blood pressure is more than 180 mmHg or less than 90 mmHg&#xD;
&#xD;
         13. Resting heart rate more than 120 bpm&#xD;
&#xD;
         14. Cardiac CT or echocardiographic evidence of thrombus in the left ventricle or left&#xD;
             atrium&#xD;
&#xD;
         15. History of bleeding diathesis or a major coagulopathy (i.e. platelet count &lt; 100,000&#xD;
             plts/ml whole blood; PTT or PT &gt; 1.3 times control value)&#xD;
&#xD;
         16. GI bleed requiring transfusion within the past 3 months&#xD;
&#xD;
         17. Patient has suffered a stroke within the past 6 months&#xD;
&#xD;
         18. Evidence of severe calcification in the VPD Implant attachment zone&#xD;
&#xD;
         19. Evidence of a significant sub-aortic obstruction (&quot;left moderator band&quot;) in the area&#xD;
             of implant&#xD;
&#xD;
         20. History of Kawasaki's disease&#xD;
&#xD;
         21. Patient has received a heart, lung, liver and/or kidney transplant&#xD;
&#xD;
         22. Patient on dialysis or expected to require hemodialysis within 12 months&#xD;
&#xD;
         23. Patient has chronic liver disease&#xD;
&#xD;
         24. Patient has received intracardiac gene therapy or stem cell therapy&#xD;
&#xD;
         25. Creatinine &gt; 2.5mg/dl or impaired renal function that places patient at risk of&#xD;
             contrast induced renal failure&#xD;
&#xD;
         26. Hypersensitivity to contrast media&#xD;
&#xD;
         27. Allergy or contraindication to clopidogrel or aspirin&#xD;
&#xD;
         28. Evidence of ongoing infection (fever with temperature &gt; 38°C and/or WBC &gt; 15,000)&#xD;
&#xD;
         29. Co-morbidities associated with a life expectancy of less than 12-months or there are&#xD;
             factors making echo and clinical follow-up difficult (no permanent address, etc.)&#xD;
&#xD;
         30. Patient is currently participating in another investigational device or drug research&#xD;
             study for which the follow-up period is not complete&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William T Abraham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Hospitals</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Heart Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dedinje Cardiovascular Institute</name>
      <address>
        <city>Belgrade</city>
        <zip>11040</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Serbia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>December 12, 2007</study_first_submitted>
  <study_first_submitted_qc>December 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2007</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>percutaneous</keyword>
  <keyword>interventional cardiology</keyword>
  <keyword>apical remodeling</keyword>
  <keyword>LV dilatation</keyword>
  <keyword>akinesis</keyword>
  <keyword>dyskinesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

